61 / 69
61
51.
Milojkovic D, Nicholson E, Apperley JF, Holyoake TL,
Shepherd P, Drummond MW, et al. Early prediction of
success or failure of treatment with second-generation
tyrosine kinase inhibitors in patients with chronic myeloid
leukemia. Haematologica 2010;95:224-31.
52.
Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A,
Howard J, et al. Monitoring patients in complete
cytogenetic remission after treatment of CML in chronic
phase with imatinib: patterns of residual leukaemia and
prognostic factors for cytogenetic relapse. Leukemia
2005;19:507-12.
53.
Furukawa T, Narita M, Koike T, Takai K, Nagai K,
Kobayashi M, et al. Clinical value of assessing the response
to imatinib monitored by interphase FISH and RQ-PCR for
BCR-ABL in peripheral blood for long-term survival of
chronic phase CML patients: results of the Niigata CML-
multi-institutional co-operative clinical study. Int J
Hematol 2011;93:336-43.
54.
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles
FJ, Wetzler M, et al. High-dose imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia: high
rates of rapid cytogenetic and molecular responses. J Clin
Oncol. 2009;27:4754-9.
55.
Ross DM, Branford S, Moore S, Hughes TP. Limited
clinical value of regular bone marrow cytogenetic analysis
in imatinib-treated chronic phase CML patients monitored
by RQ-PCR for BCR-ABL. Leukemia 2006;20:664-70.
56.
Press RD, Galderisi C, Yang R, Rempfer C, Willis SG,
Mauro MJ, et al. A half-log increase in BCR-ABL RNA
predicts a higher risk of relapse in patients with chronic
myeloid leukemia with an imatinib-induced complete
cytogenetic response. Clin Cancer Res 2007;13:6136-43
57.
Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, et
al. Quantitative reverse transcription polymerase chain